Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
NCT ID: NCT02110394
Last Updated: 2016-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
190 participants
OBSERVATIONAL
2012-06-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
NCT02072967
Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line
NCT01127841
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
NCT01754857
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
NCT00758693
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
NCT00891839
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
bendamustine and rituximab
bendamustine
Routine practice
rituximab
Routine practice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bendamustine
Routine practice
rituximab
Routine practice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed Consent Form for personal data handling signed by the program participant
Exclusion Criteria
* Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment
* Contraindications for Ribomustin usage in accordance with product label
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Study Manager
Role: STUDY_CHAIR
Astellas Pharma Europe B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Republic Clinical Hospital n.a. N.A. Semashko
Buryatia, Ulan-Ude, Russia
Alexandro-Mariinskaia Regional Clinical Hospital/13
Astrakhan, , Russia
Vologda Reginal Clinical Hospital #2
Cherepovets, , Russia
Irkutsk Regional Clinical Hospital/08
Irkutsk, , Russia
Kaliningrad City Clinical Hospital
Kaliningrad, , Russia
Regional Clinical Hospital#1/04
Khabarovsk, , Russia
District Cancer Center od Khanty -Mansiysk
Khanty-Mansiysk, , Russia
National Medical Surgical Center n.a.N.I.Pirogov/15
Moscow, , Russia
RONC n.a.N.N.Blokhin/21
Moscow, , Russia
Сentral Clinical Hospital n.a.N.A.Semashko/20
Moscow, , Russia
Central Clinical Hospital of Department of Presidential Affairs
Moscow, , Russia
Haematology Centre at Main Military Clinical Hospital n.a. N.N. Burdenko
Moscow, , Russia
Murmansk Regional Clinical Hospital n.a.P.A.Bayandin/31
Murmansk, , Russia
Nizhniy Novgorod Regional Clinical Hospital n.a.N.A.Semashko/14
Nizhny Novgorod, , Russia
Medical Radiology Scientific Center/23
Obninsk, , Russia
Omsk Regional Clinical Hospital
Omsk, , Russia
Orenburg State Medical Academy/011
Orenburg, , Russia
Perm regional hospital
Perm, , Russia
Karelia Republican Сlinical Hospital n.a.V.A.Baranov/32
Petrozavodsk, , Russia
Pskov Regional Clinical Hospital
Pskov, , Russia
Rostov Scientific Research Oncology Institution/03
Rostov-on-Don, , Russia
Site 70001 Private Practice
Saint Petersburg, , Russia
Military-Medical Academy n.a. Kirova
Saint Petersburg, , Russia
Samara State Medical University' Clinics/28
Samara, , Russia
Saratov State Medical University n.a. V.I.Razumovskiy
Saratov, , Russia
Road Clinical Hospital on Smolensk station OAO RZhD/12
Smolensk, , Russia
Komi Republican Oncology Dispensary /01
Syktyvkar, , Russia
Tula Regional Clinical Hospital/07
Tula, , Russia
Tyumen Regional Clinical Hospital#1/27
Tyumen, , Russia
Regional Clinical Hospital/26
Ulyanovsk, , Russia
Volgograd Regional Clinical Oncology Dispensary#1/25
Volgograd, , Russia
Vologda Regional Clinical Hospital
Vologda, , Russia
Yekaterinburg City Hospital #7
Yekaterinburg, , Russia
Yekaterinburg Regional Clinical Hospital #1
Yekaterinburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RU-BEN-NI-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.